LEQEMBI (lecanemab) has significant market potential due to the high global prevalence of the condition and the demand for disease-modifying treatments. With an aging population and limited ...

Leqembi’s application now moves forward to the European Commission, which will issue a formal verdict for the injection that ...

Eisai and Biogen have been unable to persuade the medicines regulator in Australia to approve their Alzheimer's disease ...

Eisai (ESAIY) and Biogen (BIIB) announced that the Therapeutic Goods Administration, TGA, of Australia has confirmed the initial decision to ...

Lecanemab is the result of a strategic research alliance between Eisai and BioArctic. It is a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody directed against aggregated soluble ...

BioArctic AB's (publ) (NASDAQ: BIOA B) (STOCKHOLM: BIOA B) partner Eisai announced today that the Therapeutic Goods Administration (TGA) ...

The European Union’s medicines regulator on Friday reiterated its positive recommendation for Eisai and Biogen’s Alzheimer’s ...

Health updates cover U.S. involvement in WHO meetings, UK approval of Moderna's RSV vaccine, a Texas measles outbreak, FDA ...

Along with Nutley-based Eisai, several other New Jersey-based giants in the space have conducted layoffs over the past few ...

SciClone will develop and distribute Tasfygo in greater China but Eisai will retain worldwide rights outside the region.

The European Commission had requested the committee consider new data on the drug that became available after it had adopted its positive opinion.